Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 20, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Anaplastic large cell lymphoma, ALK-negative.

Andrés J M Ferreri1, Silvia Govi, Stefano A Pileri

  • 1Unit of Lymphoid Malignancies, Department of Onco-Hematology, San Raffaele Scientific Institute, Milan, Italy. andres.ferreri@hsr.it

Critical Reviews in Oncology/Hematology
|July 14, 2012
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same author

SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026
Same author

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026

Anaplastic large cell lymphoma, ALK-negative (ALCL-ALK-) is an aggressive non-Hodgkin lymphoma with a poor prognosis. While chemotherapy shows some response, novel targeted agents are crucial for improving outcomes in ALCL-ALK- patients.

Area of Science:

  • Hematology
  • Oncology
  • Pathology

Background:

  • Anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK)-negative (ALCL-ALK-) is a distinct subtype of non-Hodgkin lymphoma.
  • It accounts for 2-3% of all NHL and 12% of T-cell NHL, often presenting in advanced stages with aggressive behavior.

Purpose of the Study:

  • To review the characteristics, prognostic factors, and treatment strategies for ALCL-ALK-.
  • To highlight the poor prognosis and the need for novel therapeutic approaches.

Main Methods:

  • Review of existing literature on ALCL-ALK-.
  • Analysis of clinical presentation, diagnostic criteria, prognostic indicators, and treatment outcomes.
  • Exploration of emerging therapeutic agents.

Related Experiment Videos

Last Updated: May 20, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Main Results:

  • ALCL-ALK- typically affects adults with a median age of 54-61 years and has a poor 5-year overall survival (30-49%).
  • Prognostic factors include age, International Prognostic Index, and bone marrow infiltration.
  • Standard chemotherapy (e.g., CHOP) yields limited long-term disease-free survival, necessitating further treatment options.

Conclusions:

  • ALCL-ALK- is an aggressive lymphoma with a significantly worse prognosis than ALK-positive ALCL.
  • Current chemotherapy regimens offer modest benefits, with frequent relapses.
  • Investigational therapies, including targeted agents and novel combinations, hold promise for improving patient outcomes.